236 related articles for article (PubMed ID: 12819938)
1. New approaches to the endocrine prevention and treatment of breast cancer.
Howell A; Howell SJ; Evans DG
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S39-44. PubMed ID: 12819938
[TBL] [Abstract][Full Text] [Related]
2. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
Bevers TB
J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
[TBL] [Abstract][Full Text] [Related]
3. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Dunn BK; Ryan A
Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
[TBL] [Abstract][Full Text] [Related]
6. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
Dunn BK; Ford LG
Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
[TBL] [Abstract][Full Text] [Related]
7. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
Jordan VC
Eur J Cancer; 2006 Nov; 42(17):2909-13. PubMed ID: 17064889
[TBL] [Abstract][Full Text] [Related]
8. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
Powles TJ
Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068
[TBL] [Abstract][Full Text] [Related]
9. Prevention of hormone-related cancers: breast cancer.
Dunn BK; Wickerham DL; Ford LG
J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
[TBL] [Abstract][Full Text] [Related]
10. [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].
Ricart JJ
Medicina (B Aires); 2004; 64(1):66-72. PubMed ID: 15034961
[TBL] [Abstract][Full Text] [Related]
11. The endocrine prevention of breast cancer.
Howell A
Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):615-23. PubMed ID: 18971122
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine treatment of early breast cancer.
Lønning PE
Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446
[TBL] [Abstract][Full Text] [Related]
13. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen and raloxifene may benefit women at high risk for breast cancer.
Rollins G
Rep Med Guidel Outcomes Res; 2002 Jul; 13(14):1-2, 5. PubMed ID: 12518771
[No Abstract] [Full Text] [Related]
15. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
Vogel VG
Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
[TBL] [Abstract][Full Text] [Related]
16. [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
Terán Dávila J; Teppa Garrán AD
Ginecol Obstet Mex; 2005 Aug; 73(8):424-35. PubMed ID: 16304968
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene for the treatment and prevention of breast cancer?
Pappas SG; Jordan VC
Expert Rev Anticancer Ther; 2001 Oct; 1(3):334-40. PubMed ID: 12113100
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer risk reduction: what do we know and where should we go?
Prout MN
Medscape Womens Health; 2000; 5(5):E4. PubMed ID: 11113777
[TBL] [Abstract][Full Text] [Related]
19. [Adjuvant treatment of breast cancer. Endocrine therapy].
Mouridsen HT; Andersen J
Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
[TBL] [Abstract][Full Text] [Related]
20. Risk-reducing strategies for breast cancer--a review of recent literature.
Mokbel K
Int J Fertil Womens Med; 2003; 48(6):274-7. PubMed ID: 15646397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]